Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B.
- Author:
Wen CHEN
1
;
Jin-Lin HOU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antifungal Agents; economics; therapeutic use; China; epidemiology; Cost-Benefit Analysis; DNA, Viral; blood; Drug Costs; statistics & numerical data; Economics, Pharmaceutical; Female; Hepatitis B e Antigens; blood; Hepatitis B, Chronic; complications; drug therapy; economics; epidemiology; Humans; Insurance, Long-Term Care; Lamivudine; economics; therapeutic use; Liver Cirrhosis; etiology; prevention & control; Male; Markov Chains; Middle Aged; Models, Economic; Nucleosides; economics; therapeutic use; Prescription Drugs; economics; Pyrimidinones; economics; therapeutic use; Quality-Adjusted Life Years; Thymidine; analogs & derivatives
- From: Chinese Journal of Hepatology 2009;17(8):569-573
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate long-term cost effectiveness of telbivudine and lamivudine for the treatment of CHB.
METHODSCost effectiveness was conducted from social health insurance perspective. A Markov model was established based on disease progression pattern and the data from the 2 years GLOBE clinical trial. The information of annual medical expenditure and quality-of-life assessment for different CHB-related diseases was obtained from literature. Incremental cost per life year or quality-adjusted life year gained was measured.
RESULTSCompared with lamivudine, the incremental cost for 1 additional QALY gained with telbivudine in treating HBeAg-positive and -negative CHB were 5403 yuan and 28239 yuan in Beijing, as well 4916 yuan and 29618 yuan in Guangzhou, respectively. According to national economic burden of CHB-related diseases, the ICER with telbivudine vs lamivudine were 1282 yuan and 31565 yuan for HBeAg-positive and -negative CHB.
CONCLUSIONAccording to WHO recommendation for ICER threshold, telbivudine is cost effective in treating HBeAg-positive and -negative CHB, as compared to lamivudine.
